Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-masked, Vehicle-controlled Study of LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease

Next Previous
X
Search
Trial Profile

A Randomized, Double-masked, Vehicle-controlled Study of LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Licaminlimab (Primary)
  • Indications Dry eyes
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Alcon

    • Most Recent Events

    • 04 Sep 2024 Results evaluate the pharmacogenomics of response to topical ocular tumor necrosis factor alpha (TNFalpha) inhibitor licaminlimab in patients with DED published in the Cornea
    • 23 Aug 2022 According to an Oculis media release, results have been published by the Clinical Ophthalmology journal.
    • 23 Aug 2022 Results published in Oculis Pharma Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top